RCEL News & Events

Reports Q1 revenue $19.3M, consensus $24.65M. Cary Vance, CEO, commented: "Since November, we've stabilized the business, improved how we operate, and delivered a solid start to 2026. With sequential revenue growth and improving ordering patterns across the portfolio, we are focused on delivering sustained performance as we move through the year. At April's American Burn Association annual meeting, it was exciting to see how our products, RECELL, Cohealyx and PermeaDerm, are delivering meaningful outcomes for clinicians and their patients. I am incredibly proud and excited to lead AVITA as we continue to build towards the future of wound care."

FY26 revenue is expected to be in the range of $80M-$85M, representing growth of approximately 12%-19% compared to FY25 revenue.

Avita Medical announced that its board of directors has appointed Cary Vance as president and CEO, effective immediately. The board of directors has also appointed Jan Stern Reed as its chair, effective immediately. Vance, who has served as interim CEO since October 2025, will continue to serve on the board as an executive member. Vance has served on the Avita Medical board of directors since 2023 and was previously appointed chairman in 2025.